Shock Waves for Treatment of Gynoid Lipodystrophy and Localized Fat

Learn more about:
Related Clinical Trial
Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil Effect of Berberine on Metabolic Syndrome, Efficacy and Safety in Combination With Antiretroviral Therapy in PLWH. Hemoglobin Level, Coagulopathy Profile and Electrolyte Balance Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome Exercise and Pioglitazone for HIV-Metabolic Syndromes Observational Study of Changes in Fat Distribution and Blood Metabolites in HIV Infected Adults Yoga for the Management of HIV-Metabolic Syndromes Pravastatin for Hyperlipidaemia in HIV. A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth Exercise for Patients With HIV Infections Lactate Metabolism Study in HIV Infected Persons Quality of Life, Sleep, and Biomarkers in People With HIV/AIDS The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients Safety Study of Antria Cell Preparation Process to Enhance Facial Fat Grafting With Adipose Derived Stem Cells Growth Hormone Dynamics and Cardiac Steatosis in HIV The Effect of Anti-HIV Treatment on Body Characteristics of HIV-Infected Children Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir. Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers Detraining in People Living With HIV/AIDS SHARE: Simple HAART With Abacavir, Reyataz, and Epivir The Effects of Anabolic Steroids and Protease Inhibitors on People Living With HIV/AIDS Observational Study of Fat Loss in HIV Infected Adults Taking Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Metabolism and Body Shape of Healthy Children and Children With Chronic Infections Changing to Nonprotease Inhibitor Treatment to Improve Side Effects Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids Perceived Changes in Body Build and Image in Patients Who Are Now Taking or Recently Have Stopped Taking Anti-HIV Drugs White Light Scanning to Aid Body Contouring: A Pilot Project Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients Study Comparing Reducing the Dose of Stavudine Versus Switching to Tenofovir in HIV-Infected Patients Receiving Antiretroviral Therapy The Cleveland Cardiometabolic Cohort Metabolic Abnormalities in HIV-infected Persons Clinical Evaluation of Venus Versa Octipolar Applicator for Reduction of Abdomen Circumference Factors Mediating Gut Microbiota Dysbiosis and Metabolic Disease in HIV Patients. Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome Effects of Short-term Growth Hormone in HIV-infected Patients Safety Study of Filler Agent Composed of Autologous Mesenchymal Stem Cells and Hyaluronic Acid Raltegravir Therapy for Women With HIV and Fat Accumulation The PREFORM Study: A Study to Evaluate the Safety and Efficacy of Rotational Fractional Resection on Submental Contouring Effects of IGF-I in HIV Metabolic Disease Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults Lopinavir/r Monotherapy Versus Abacavir/Lamivudine and Lopinavir/r for Limb Fat Recovery in Persons With Lipoatrophy Effects of Growth Hormone Releasing Hormone in HIV A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy Body Composition and Adipose Tissue in HIV Study to Evaluate Changes in Limb Fat When Switching From a Thymidine Analogue CONFORM: Rotational Fractional Resection for Submental Contouring Study of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy TH9507 in Patients With HIV-Associated Lipodystrophy TH9507 Extension Study in Patients With HIV- Associated Lipodystrophy Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy Energy Expenditure of People Living With HIV/AIDS Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Egrifta Replacement and Sleep Disordered Breathing Clinical Trial to Determine the Efficacy of Sculptra™ Dermal Filler for the Correction of Contour Deformities Caused by Lipoatrophy Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients Low Energy Diet and Familial Partial Lipodystrophy Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy Adipocyte, Insulin-resistance and Immunity : Evaluation of Interleukin-7 in Lipodystrophy, Diabetes and Obesity Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy Role of the Autonomic Nervous System in HIV-Lipodystrophy Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome Therapeutic Approaches to HAART-Induced Lipodystrophy Different Surgical Modalities for Thigh Lipodystrophy Including Liposuction,Thigh Lift and Liposuction Assisted Thigh Lift Leptin to Treat Lipodystrophy Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy Prevalence of Lipodystrophy Syndrome and Its Role as Cause of Metabolic Disturbances Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension Shock Waves for Treatment of Gynoid Lipodystrophy and Localized Fat Corticosteroid-induced Lipodystrophy and Adipokines Short-term Effects of Leptin in People With Lipodystrophy Leptin to Treat Lipodystrophy Lipodystrophy Connect Patient Registry An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy Autologous Adipose-Derived Stem Cell Transplantation in Patients With Lipodystrophy

Brief Title

Shock Waves for Treatment of Gynoid Lipodystrophy and Localized Fat

Official Title

Effect of Extracorporeal Shock Wave Therapy in the Treatment of Gynoid Lipodystrophy and Localized Fat

Brief Summary

      PURPOSE: To evaluate the efficacy of shock waves extracorporea in improving body
      contour,decrease fat localized and appearance of gynoid lipodystrophy.

      SUBJECTS AND METHODS: A prospective and comparative longitudinal clinical study will be
      performed in 30 women with localized fat and gynoid lipodystrophy. Patients will be submitted
      data collection and assessments and before and after treatment.

      HYPOTHESES: It is expected that the patients will present improvement in the body contour,
      decrease fat localized and in the picture of the gynoid lipodystrophy after of the therapies.

      STATISTICAL ANALYSIS: A descriptive analysis will be done before and after
      vibration-oscillatory therapy, with frequency tables for categorical and descriptive
      variables (mean, standard deviation, median, minimum and maximum values) for continuous or
      numerical variables. In order to compare the main variables between the groups and the
      collection times, the analysis of variance (ANOVA) for repeated measurements will be used.
      Tukey's test will be used to compare groups. The level of significance adopted for the
      statistical tests will be 5% or p <0.05.
    

Detailed Description

      After signing the informed consent, the participants will be evaluated by two
      physiotherapists where the data collected will be personal data, anthropometrics and
      complementary diagnostic tests, such as: ultrasound diagnosis to evaluate the thickness of
      the adipose tissue and Cutomiter analysis of the Viscoelasticity of skin. They then started
      treatment with another physiotherapist who will perform the following study protocol: placing
      a light layer of neutral gel on the treatment area, applying extracorporeal shock waves with
      the stainless steel tip with 180mJ of energy totaling 4 thousand shots , in abdomens,
      buttocks and posterior thigh and 2 thousand shots in flanks, then performs the change of the
      tip to the plastic and performs 2 thousand shots in the regions of abdomens, buttocks,
      posterior thigh emil shots in the region of flanks. The protocol will be performed twice a
      week for 1 and 20 hours each, totaling 10 sessions.
    


Study Type

Interventional


Primary Outcome

Anthropometric evaluation


Condition

Lipodystrophy

Intervention

THORK Shock Wave® (Extracorporeal shock waves)

Study Arms / Comparison Groups

 Extracorporeal shock waves
Description:  Composed of 30 female patients with glandular lipodystrophy in the buttocks and posterior thigh and fat located in abdomen and flanks that received the treatment of extracorporeal shock waves with energy between 100 and 180mJ, frequency of 15Hz and 6000 shots in abdomen, glutes and thigh Back and flanks 3000 shots with radial applicator and 15mm tip. The treatment is performed twice a week for 1 hour and 30 minutes each session.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Device

Estimated Enrollment

30

Start Date

April 3, 2017

Completion Date

December 1, 2018

Primary Completion Date

January 1, 2018

Eligibility Criteria

        Inclusion Criteria:

          -  Women older than 18 years of age up to premenopausal age (50 years of age).

          -  With body mass index considered eutrophic and / or overweight.

          -  Patients with lipodystrophy and localized abdominal fat.

          -  non smokers.

          -  Who agree to participate and sign the informed consent form.

        Exclusion Criteria:

          -  Male gender.

          -  Possible.

          -  Haemophilia carriers and hemorrhagic disorders.

          -  Carriers diabetes mellitus.

          -  Women in menopause.

          -  Performed aesthetic treatment in the gluteal, thigh and abdominal regions in the last
             1 months.

          -  Patients with skin lesions, such as dermatitis and dermatoses.

          -  Patients with acute deep vein thrombosis (DVT).

          -  About or close to cancerous lesions.

          -  Patients with cardiac pacemaker or other implanted electronic device.
      

Gender

Female

Ages

18 Years - 50 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Débora O Modena, M.S, , 

Location Countries

Brazil

Location Countries

Brazil

Administrative Informations


NCT ID

NCT03275259

Organization ID

Ibramed -SW


Responsible Party

Sponsor

Study Sponsor

Indústria Brasileira Equipamentos Médicos - IBRAMED


Study Sponsor

Débora O Modena, M.S, Principal Investigator, Ibramed - Industria Brasileira de Equipamentos Médicos


Verification Date

March 2019